4//SEC Filing
Wood Gavin 4
Accession 0001104659-20-042012
CIK 0001621227other
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 7:06 PM ET
Size
8.4 KB
Accession
0001104659-20-042012
Insider Transaction Report
Form 4
Wood Gavin
Chief Financial Officer
Transactions
- Award
Option to purchase Ordinary Shares
2020-04-01+565,000→ 565,000 totalExercise: $0.00Exp: 2030-04-01→ Ordinary Shares (565,000 underlying) - Award
Option to purchase Ordinary Shares
2020-04-01+2,500,000→ 2,500,000 totalExercise: $0.45Exp: 2030-04-01→ Ordinary Shares (2,500,000 underlying)
Footnotes (4)
- [F1]The exercise price was converted from GBP0.36 based on an exchange rate of U.S.$1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 625,000 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in monthly installments of 52,080 Ordinary Shares on the first of each month from May 1, 2021 through March 1, 2024 and 52,200 Ordinary Shares on April 1, 2024.
- [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Exercisable as to 141,250 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in annual installments of 141,250 Ordinary Shares on the first of each April from April 1, 2022 through April 1, 2024.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
Related Parties
1- filerCIK 0001577539
Filing Metadata
- Form type
- 4
- Filed
- Mar 31, 8:00 PM ET
- Accepted
- Apr 1, 7:06 PM ET
- Size
- 8.4 KB